JP5663476B2 - 新規ピロロ［２，３−ａ］カルバゾールおよびＰＩＭキナーゼ阻害剤としてのそれらの使用 - Google Patents

新規ピロロ［２，３−ａ］カルバゾールおよびＰＩＭキナーゼ阻害剤としてのそれらの使用 Download PDF

Info

Publication number
JP5663476B2
JP5663476B2 JP2011515526A JP2011515526A JP5663476B2 JP 5663476 B2 JP5663476 B2 JP 5663476B2 JP 2011515526 A JP2011515526 A JP 2011515526A JP 2011515526 A JP2011515526 A JP 2011515526A JP 5663476 B2 JP5663476 B2 JP 5663476B2
Authority
JP
Japan
Prior art keywords
dihydropyrrolo
carbazole
carbaldehyde
group
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011515526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526610A (ja
JP2011526610A5 (https=
Inventor
アニゾン，ファブリース
モロー，パスカル
プルドム，ミッシェル
コーヘン，フィリップ
アボアボ，ベッティーナ
アク−ゲドゥ，ルフィン
ロシニョル，エミリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2011526610A publication Critical patent/JP2011526610A/ja
Publication of JP2011526610A5 publication Critical patent/JP2011526610A5/ja
Application granted granted Critical
Publication of JP5663476B2 publication Critical patent/JP5663476B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011515526A 2008-07-03 2009-06-25 新規ピロロ［２，３−ａ］カルバゾールおよびＰＩＭキナーゼ阻害剤としてのそれらの使用 Expired - Fee Related JP5663476B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0803752A FR2933409B1 (fr) 2008-07-03 2008-07-03 NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
FR0803752 2008-07-03
PCT/FR2009/000788 WO2010000978A1 (fr) 2008-07-03 2009-06-25 NOUVEAUX PYRROLO [2,3-a] CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM

Publications (3)

Publication Number Publication Date
JP2011526610A JP2011526610A (ja) 2011-10-13
JP2011526610A5 JP2011526610A5 (https=) 2012-08-02
JP5663476B2 true JP5663476B2 (ja) 2015-02-04

Family

ID=40328682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515526A Expired - Fee Related JP5663476B2 (ja) 2008-07-03 2009-06-25 新規ピロロ［２，３−ａ］カルバゾールおよびＰＩＭキナーゼ阻害剤としてのそれらの使用

Country Status (7)

Country Link
US (1) US8481586B2 (https=)
EP (1) EP2326649B1 (https=)
JP (1) JP5663476B2 (https=)
AT (1) ATE551344T1 (https=)
CA (1) CA2729690A1 (https=)
FR (1) FR2933409B1 (https=)
WO (1) WO2010000978A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
KR101488565B1 (ko) 2011-12-07 2015-02-03 주식회사 두산 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
KR101452579B1 (ko) * 2012-08-17 2014-10-21 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
KR101537436B1 (ko) 2012-08-17 2015-07-17 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
JP2021521170A (ja) 2018-04-13 2021-08-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
KR20260008165A (ko) 2019-02-12 2026-01-15 스미토모 파마 아메리카, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057979A1 (es) * 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
US20070117804A1 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors

Also Published As

Publication number Publication date
ATE551344T1 (de) 2012-04-15
FR2933409B1 (fr) 2010-08-27
US8481586B2 (en) 2013-07-09
EP2326649B1 (fr) 2012-03-28
EP2326649A1 (fr) 2011-06-01
WO2010000978A1 (fr) 2010-01-07
JP2011526610A (ja) 2011-10-13
US20110263669A1 (en) 2011-10-27
FR2933409A1 (fr) 2010-01-08
CA2729690A1 (fr) 2010-01-07

Similar Documents

Publication Publication Date Title
JP5663476B2 (ja) 新規ピロロ［２，３−ａ］カルバゾールおよびＰＩＭキナーゼ阻害剤としてのそれらの使用
KR101216323B1 (ko) Ｃ?ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 헤테로시클릭 화합물 및 조성물
JP5546693B2 (ja) ピラゾロキノリン誘導体
JP2018515434A (ja) サイクリン依存性キナーゼの阻害剤
CN101282975A (zh) 作为蛋白激酶抑制剂的化合物和组合物
JP2006507292A (ja) 抗増殖活性（ｉｉ）を有するピリミド化合物
CN109641887B (zh) 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物
KR20080108353A (ko) 단백질 키나제 억제제로서의 화합물 및 조성물
PT1896470E (pt) Derivados de pirrolopiridina como inibidores de proteína-quinase
EP4010330B1 (en) Quinoline derivatives as protein kinase inhibitors
JP7336505B2 (ja) さらなる置換トリアゾロキノキサリン誘導体
TW202112784A (zh) 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
KR20260028873A (ko) Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
CN105073752B (zh) 制备三环化合物的方法以及可通过所述制备方法制备的三环化合物
JP6282017B2 (ja) Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
TW201103905A (en) 5-alkynyl-pyridines
JP7110325B2 (ja) インドールアミン ２，３－ジオキシゲナーゼ及び／又はトリプトファン ２，３－ジオキシゲナーゼの阻害剤
CA2602303A1 (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
Vasilin et al. 3-Amino (azido)-4, 6-aryl (hetaryl) thieno [2, 3-b] pyridines and benzo (furo, thieno)[c] thieno [2, 3, 4-i, j]-2, 7-naphthyridines on their basis: synthesis, spectral properties, and prediction of biological activity
JP2020519647A (ja) グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換複素環式化合物
WO2022048551A1 (zh) 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
Jadhav et al. Imidazole [1, 2-a] pyridine derivatives as selective COX-2 inhibitors.
CA2580203A1 (en) Tricycles, their manufacture and use as pharmaceutical agents
CA3146406A1 (en) Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
HK1260037B (zh) 取代的三环杂环化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141208

R150 Certificate of patent or registration of utility model

Ref document number: 5663476

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees